GAS8 Antibody | CSB-PA289923

(No reviews yet) Write a Review
SKU:
CSB-PA289923
Availability:
3 to 7 Working Days
  • GAS8 Antibody
  • The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA289923 (GAS8 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: ×200)
  • The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using CSB-PA289923 (GAS8 Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: ×200)
€315.80 - €488.70

Description

GAS8 Antibody | CSB-PA289923 | Cusabio

GAS8 Antibody is Available at Gentaur Genprice with the fastest delivery.

Online Order Payment is possible or send quotation to info@gentaur.com.

Product Type: Polyclonal Antibody

Target Names: GAS8

Aliases: growth arrest-specific 8

Background: This gene includes 11 exons spanning 25 kb and maps to a region of chromosome 16 that is sometimes deleted in breast and prostrate cancer. The second intron contains an apparently intronless gene, C16orf3, that is transcribed in the opposite orientation. This gene is a putative tumor suppressor gene. Several transcript variants encoding different isoforms have been found for this gene.

Isotype: IgG

Conjugate: Non-conjugated

Clonality: Polyclonal

Uniport ID: O95995

Host Species: Rabbit

Species Reactivity: Human, Mouse, Rat

Immunogen: Synthetic peptide of human GAS8

Immunogen Species: Human

Applications: ELISA, IHC

Tested Applications: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

Purification Method: Antigen affinity purification

Dilution Ratio1: ELISA:1:2000-1:5000

Dilution Ratio2: IHC:1:50-1:200

Dilution Ratio3:

Dilution Ratio4:

Dilution Ratio5:

Dilution Ratio6:

Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol

Form: Liquid

Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Initial Research Areas: Signal Transduction

Research Areas: Cancer;Signal transduction

View AllClose

0 Reviews

View AllClose